The MATCH Steering Committee - ACETYLSALICYLIC ACID (ASA) PROVIDES NO ADDITIONAL CLINICAL BENEFIT IN HIGH RISK PATIENTS
The MATCH Steering Committee - ACETYLSALICYLIC ACID (ASA) PROVIDES NO ADDITIONAL CLINICAL BENEFIT IN HIGH RISK PATIENTS WITH STROKE OR TIA WHEN ADDED TO CLOPIDOGREL AND OTHER STANDARD THERAPIES Mannheim, Germany May 13, 2004 - Results of the MATCH trial (Management of ATherothrombosis with Clopidogrel in High Risk Patients with recent transient ischemic attack (TIA) or ischemic stroke (IS)) announced today at the 13th European Stroke conference in Mannheim-Heidelberg, Germany, show that acetylsalicylic acid (ASA) when added to clopidogrel and other standard prevention therapies in high-risk